BioWorld

Aug. 10, 2006

View Archived Issues

Medicure Acquires Marketed CV Drug Aggrastat From MGI

As a complement to its lead cardiovascular drug, MC-1, Medicure Inc. acquired rights to its first marketed product, Aggrastat, a glycoprotein IIb/IIIa inhibitor to treat acute coronary syndrome. (BioWorld Today) Read More

HGS Outlines LymphoStat-B's Phase III Plan; Riquent Returns

Read More

CpGs Tweak Cells Toward Innate, Adaptive Immunity

Read More

Altor Moving To Clinic With T-Cell Receptor-Based Drug

Read More

Clinic Roundup

Read More

Other News To Note

Read More